What treatments reduce kidney stone risk in patients with bowel disease?

Area of Science:

• Nephrology
• Gastroenterology
• Urology

Background:

• Patients with bowel disease often develop kidney stones, frequently due to enteric hyperoxaluria (EH).
• Therapeutic strategies aim to decrease stone risk in this population, but their effectiveness varies.

Purpose of the Study:

• To examine physician therapeutic choices for decreasing stone risk in patients with bowel disease without colon resection.
• To evaluate the impact of fluid intake, alkali supplementation, and oxalate-focused interventions on urine characteristics and stone risk.

Main Methods:

• Analysis of clinic records and 24-h urine collections from 100 stone formers with bowel disease.
• Multivariate linear regression and t tests were used to compare intervention effects.
• Interventions included advice on fluid intake, alkali supplementation, and oxalate absorption reduction.

Main Results:

• Patients advised to increase fluid intake showed significantly greater increases in urine volume compared to controls (0.7 vs. 0.3 L/day, p=0.03).
• Increased fluid intake led to a decrease in calcium oxalate supersaturation (CaOx SS).
• Alkali supplementation and oxalate-focused advice did not significantly alter urine pH, citrate, or CaOx SS.

Conclusions:

• Physician treatment choices were guided by baseline urine characteristics.
• Increased fluid intake is an effective strategy for managing stone risk in patients with bowel disease.
• Alkali and oxalate interventions were found to be ineffective in this patient cohort.